Phrontline Biopharma Starts Phase I/II Trials for Dual-Payload ADC TJ102#China#Hangzhou#Phrontline_Biopharma#bispecific_ADC#TJ102
Phrontline Biopharma Starts Phase I/II Trials for Dual-Payload ADC TJ102
Phrontline Biopharma announces the start of its Phase I/II trial for TJ102, a bispecific ADC aimed at treating ovarian cancer and solid tumors.
third-news.com
September 30, 2026 at 2:18 PM
Phrontline Biopharma Starts Phase I/II Trials for Dual-Payload ADC TJ102#China#Hangzhou#Phrontline_Biopharma#bispecific_ADC#TJ102